국제약품

002720KOSPI의약품 제조업

49.0 / 100

Reference Date: 2026-04-13

Financial Score16.5 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is above the industry average but the high debt ratio poses financial risk. Slightly down 1.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Korea Pharmaceutical Co., Ltd. is a company engaged in the manufacture and sale of specialty and general pharmaceuticals, including Quron Eye Drops and Colensina Soft Capsules. With headquarters in Seongnam and manufacturing/R&D facilities in Ansan, the company achieved a 12.2% increase in consolidated sales to 175,496 million won in fiscal year 2025, while conducting 5 ongoing drug development projects.

Number of Employees

272people

Average Salary

68.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

17.34Industry Average 14.803.0Point

Higher than industry avg (caution)

PBR

1.05Industry Average 1.042.5Point

Higher than industry avg (caution)

ROE

6.09Industry Average 4.424.0Point

In line with industry avg

Debt Ratio

23.09Industry Average 11.980.5Point

1.9x industry avg (risky)

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲13.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲214.6% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.5% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position6.0Point

52w upper range (66%)

Current 4,855Won52-week high 5,23052-week low 4,100

1-month return3.0Point

1m -1.52% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26
Neutral사업보고서 (2025.12)2026-03-18
Neutral감사보고서제출2026-03-17